Valion Bio, Inc. Accounts Receivable
Valion Bio, Inc. (VBIO) had Accounts Receivable of $19.00 thousand as of 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2025-11-14
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $19.00K.
- 2025-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $13.00K.
- 2025-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $13.00K.
- 2024-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $69.00K.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current | Accounts Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2025-09-30 | $19.00K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $13.00K 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $13.00K 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $69.00K 10-Q · filed 2025-11-14 | |
| 2024-09-30 | $9.00K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $16.00K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $74.00K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $174.00K 10-K · filed 2025-03-21 | |
| 2023-09-30 | $131.00K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $13.00K 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $57.00K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $107.00K 10-K · filed 2024-03-25 | $88.00K 10-K · filed 2023-03-31 |
| 2022-09-30 | $95.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $92.00K 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $117.00K 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $92.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |